Page 18 - Ace2 News Today

Cannabinoid receptor agonist shows potential protective effect on SARS-CoV-2-infected human heart cells As scientists continue to search for effective antidotes to direct and indirect damage caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server demonstrates the potential of cannabinoid receptor agonists to alleviate myocardial damage in this condition even in the absence of any inhibitory effect on viral in...

Fool the novel coronavirus once and it can't cause infection of cells, new research suggests.

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection? Common immunization routes for coronavirus disease 2019 (COVID-19) vaccine candidates range from intramuscular, nasal and oral to intradermal. Now, scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced an...

Proteases modulate SARS-CoV-2 spike protein activation and deactivation Proteases are enzymes that catalyze the break-down of proteins by hydrolysis and are key to the infection process of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The spike protein that initially interacts with the ACE2 receptor on the surface of host cells must undergo cleavage to initiate a conformational change that allows entry into the cell. Proteolysis can be facilitated, and has been identified to...

Gold nanoparticles investigated as part of in vitro tool for SARS-CoV-2 drug screening Scientists have measured the interaction of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein with nano-gold colloids. These nanoparticles functionalized with the S protein have different spectroscopic signals allowing for new information about the protein to be extracted. The on-going pandemic COVID-19 (coronavirus disease 2019), caused by the SARS-CoV-2, has caused over 111 ...

Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.

In the study published in the journal Integrative Physiology, the researchers found that a high intake of polyphenols may have a protective effect on patients with COVID-19 and prevent disease progression.

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

Researchers test the therapeutic efficacy of potential COVID-19 interventions in mouse models Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models. For the first study, the researchers hope to determine the survival advantage conferred by a therapeutic. Related Stories For this study, the researcher...

O-glycosylation of SARS-CoV-2 spike protein in insect and human cell lines Sites of O-glycosylation on the spike protein were near N-glycosites, suggesting O-glycans complement N-glycans effect in immune shielding. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the COVID-19 pandemic, has some characteristics that were not seen before in human coronaviruses, such as mutation on the receptor-binding domain (RBD) for high affinity to the human angiotensin-converting...